Sarah E. James MD PhD (She/Her) (@drjmdphd) 's Twitter Profile
Sarah E. James MD PhD (She/Her)

@drjmdphd

Radiation Oncologist. Mayo Sister. Friend of God. Views are my own.

ID: 899049301

calendar_today23-10-2012 03:03:45

1,1K Tweet

894 Takipçi

1,1K Takip Edilen

Radiotherapy & Oncology (@ro_greenjournal) 's Twitter Profile Photo

Retro review on #BRCA & local recurrence after skin-sparing mastectomy: BRCA carriers younger & had earlier-stage cancer No clear difference in local recurrence rates Chemo & RT linked to lower recurrence More research needed! 🔗 sciencedirect.com/science/articl… #BreastCancer #RadOnc

Adam Grant (@adammgrant) 's Twitter Profile Photo

A reliable way to boost cognitive functioning: Go to the gym. 383 studies: Exercise improves attention, memory, and information processing. It’s true across age groups and different types of workouts. Physical activity is good for the mind. Moving sharpens thinking.

A reliable way to boost cognitive functioning: Go to the gym.

383 studies: Exercise improves attention, memory, and information processing. It’s true across age groups and different types of workouts.

Physical activity is good for the mind. Moving sharpens thinking.
Mayo Clinic Arizona Radiation Oncology (@mayoazradonc) 's Twitter Profile Photo

Congrats to Dr. Yi Rong, PhD, and Nathan Yu, MD, on their podcast episode for Practical Radiation Oncology titled “Improving Consistency and Reducing Human Bias for Physicians’ Target Contouring using AI Auto-Segmentation.”

Congrats to Dr. Yi Rong, PhD, and Nathan Yu, MD, on their podcast episode for Practical Radiation Oncology titled “Improving Consistency and Reducing Human Bias for Physicians’ Target Contouring using AI Auto-Segmentation.”
Robin Zon, MD, FACP, FASCO (@ascopres) 's Twitter Profile Photo

It was an honor to discuss the critical topic of oncologist well-being on this podcast. We covered key stressors and ASCO-proposed solutions, such as eliminating low-value work, restructuring teams, promoting work-life integration, and fostering community within organizations.

Gianrico Farrugia (@gfarrugiamd) 's Twitter Profile Photo

Bold. Forward. Unbound. in Arizona will physically and digitally transform healthcare to support Category-of-One healthcare for our patients. Read more: mayocl.in/41i0beK

Bold. Forward. Unbound. in Arizona will physically and digitally transform healthcare to support Category-of-One healthcare for our patients. Read more:  mayocl.in/41i0beK
Giulia Marvaso (@giuliamarvaso84) 's Twitter Profile Photo

🔔📣📢 RADIOSA full paper is finally out! Read our publication now online on The Lancet Oncology! Randomised trial in the metachronous oligomets hormone-sensitive PCa setting reporting improved clinical PFS with the combination of SBRT and a short course of ADT!

🔔📣📢 RADIOSA full paper is finally out! Read our publication now online on <a href="/TheLancetOncol/">The Lancet Oncology</a>! Randomised trial in the metachronous oligomets hormone-sensitive PCa setting reporting improved clinical PFS with the combination of SBRT and a short course of ADT!
Mayo Clinic Arizona Radiation Oncology (@mayoazradonc) 's Twitter Profile Photo

📢 Excited to share our latest publication: "Comprehensive Analysis of Treatment Approaches in Chest Wall Ewing Sarcoma: The Impact of Tumor Volume on Oncologic Outcomes." See comments for more info… #MayoClinic #RadOnc #EwingSarcoma

📢 Excited to share our latest publication: "Comprehensive Analysis of Treatment Approaches in Chest Wall Ewing Sarcoma: The Impact of Tumor Volume on Oncologic Outcomes." 
See comments for more info…
#MayoClinic #RadOnc #EwingSarcoma
Matteo Lambertini, MD PhD (@matteolambe) 's Twitter Profile Photo

Previously presented at #ESMO24 and now published in Journal of Clinical Oncology results of a large French study providing further evidence on the importance of endocrine therapy persistence in HR+ early #BreastCancer particularly for young women Link: ascopubs.org/doi/pdf/10.120… OncoAlert #bcsm

Previously presented at #ESMO24 and now published in <a href="/JCO_ASCO/">Journal of Clinical Oncology</a> results of a large French study providing further evidence on the importance of endocrine therapy persistence in HR+ early #BreastCancer particularly for young women

Link:
ascopubs.org/doi/pdf/10.120…

<a href="/OncoAlert/">OncoAlert</a> #bcsm
Sushil (@sushilberiwal) 's Twitter Profile Photo

PORTEC 4a results . High risk benefits from EBRT ( only 25% had LND) and low risk has small but non inferior difference in vaginal recurrence with VBT DrKamrava Andrew Keller

PORTEC 4a results . High risk benefits from EBRT ( only 25% had LND) and low risk has small but non inferior difference in vaginal recurrence with VBT <a href="/KamravaMD/">DrKamrava</a> <a href="/AndrewKellerMD/">Andrew Keller</a>
Fumiko Ladd Chino, MD, FASCO (@fumikochino) 's Twitter Profile Photo

Deeply saddened that the entire team NCI Cancer Control National Cancer Institute PDQ Cancer Information has been eliminated. Our evidence-based summaries were updated throughout the year with the latest evidence and supported informed decision making between clinicians & patients across the US. 🇺🇸

Deeply saddened that the entire team <a href="/NCICancerCtrl/">NCI Cancer Control</a> <a href="/theNCI/">National Cancer Institute</a> PDQ Cancer Information has been eliminated. 

Our evidence-based summaries were updated throughout the year with the latest evidence and supported informed decision making between clinicians &amp; patients across the US. 🇺🇸
Joe Y Chang (@joechangmd) 's Twitter Profile Photo

First phase III randomized study showed an improvement in overall survival with proton-based IMPT compared to photon IMRT in head and neck cancer. This was presented today during the The Particle Therapy Co-Operative Group (PTCOG) plenary session by Steven J. Frank, MD. The exciting data provides justification for IMPT.

First phase III randomized study showed an improvement in overall survival with proton-based IMPT compared to photon IMRT in head and neck cancer. This was presented today during the <a href="/PTCOG_Official/">The Particle Therapy Co-Operative Group (PTCOG)</a> plenary session by <a href="/SJFrankMD/">Steven J. Frank, MD</a>. The exciting data provides justification for IMPT.
Sushil (@sushilberiwal) 's Twitter Profile Photo

Finally one positive data on breast cancer for oligoprogression. Focused only on HR positive breast cancer unlike previous studies with goal to continue same systemic treatment #bcsm